Risk factors for recurrence of primary sclerosing cholangitis after living donor liver transplantation in Japanese registry

American Journal of Transplantation

Volumn 11, Issue 3, 2011, Pages 518-527

  Egawa, Hiroto ^a   Ueda, Y ^b   Ichida, T ^c   Teramukai, S ^d   Nakanuma, Y ^e   Onishi, S ^f   Tsubouchi, H ^g  

^a ASAHI UNIVERSITY   (Japan)

^b KYOTO UNIVERSITY   (Japan)

^c JUNTENDO UNIVERSITY   (Japan)

^d KYOTO UNIVERSITY HOSPITAL   (Japan)

^e KANAZAWA UNIVERSITY   (Japan)

^f KOCHI MEDICAL SCHOOL   (Japan)

^g KAGOSHIMA UNIVERSITY   (Japan)

Author keywords

Biliary complication; Cytomegalovirus (CMV); Graft loss; Living donor transplantation; MELD score; Primary sclerosing cholangitis; Recurrent disease; Related donation

Indexed keywords

CALCINEURIN INHIBITOR; CORTICOSTEROID; CYCLOSPORIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS;

ADULT; AGE DISTRIBUTION; ARTERY THROMBOSIS; ARTICLE; BILE DUCT BYPASS; BILE DUCT CARCINOMA; BLOOD GROUP ABO SYSTEM; BLOOD GROUP INCOMPATIBILITY; CHOLEDOCHOJEJUNOSTOMY; CORTICOSTEROID THERAPY; CYTOMEGALOVIRUS; DISEASE REGISTRY; ENTERITIS; FEMALE; GENDER; GRAFT RECIPIENT; GRAFT SURVIVAL; HEPATIC ARTERY; HLA MATCHING; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; JAPANESE; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; LIVING DONOR; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PRIMARY SCLEROSING CHOLANGITIS; PRIORITY JOURNAL; QUESTIONNAIRE; RECURRENT DISEASE; RISK FACTOR;

ADOLESCENT; ADULT; AGED; ASIAN CONTINENTAL ANCESTRY GROUP; CHILD; CHILD, PRESCHOOL; CHOLANGITIS, SCLEROSING; FEMALE; GRAFT REJECTION; HUMANS; INFANT; LIVER TRANSPLANTATION; LIVING DONORS; MALE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; RECURRENCE; REGISTRIES; RETROSPECTIVE STUDIES; RISK FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 79951962801     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2010.03402.x     Document Type: Article

References (32)

1. Vera A, Moledina S, Gunson B et al. Risk factors for recurrence of primary sclerosing cholangitis of liver allograft. Lancet 2002; 360: 1943-1944. (Pubitemid 35472138)
2. Khettry U, Keaveny A, Goldar-Najafi A et al. Liver transplantation for primary sclerosing cholangitis: A long-term clinico-pathologic study. Mum Pathol 2003; 34: 1127-1136. (Pubitemid 37466998)
3. Kugelmas M, Spiegelman P, Osgood MJ et al. Different immunosuppressive regimens and recurrence of primary sclerosing cholangitis after liver transplantation. Liver Transpl 2003; 9: 727-732. (Pubitemid 36874461)
4. Brandsaeter B, Schrumpf E, Bentdal O et al. Recurrent primary sclerosing cholangitis after liver transplantation: A magnetic resonance cholangiography study with analyses of predictive factors. Liver Transpl 2005; 11: 1361-1369. (Pubitemid 43071585)
5. Cholongitas E, Shusang V, Papatheodoridis GV et al. Risk factors for recurrence of primary sclerosing cholangitis after liver transplantation. Liver Transpl 2008; 14: 138-143. (Pubitemid 351267268)
6. Alexander J, Lord JD, Yeh MM et al. Risk factors for recurrence of primary sclerosing cholangitis after liver transplantation. Liver Transpl 2008; 14: 245-251. (Pubitemid 351267284)
7. Campsen J, Zimmerman MA, Trotter JF et al. Clinically recurrent primary sclerosing cholangitis following liver transplantation: A time course. Liver Transpl 2008; 14: 181-185. (Pubitemid 351267274)
8. Alabraba E, Nightingale P, Gunson B et al. A re-evaluation of the risk factors for the recurrence of primary sclerosing cholangitis in liver allografts. Liver Transpl 2009; 15: 330-340.
9. Gordon F. Recurrent primary sclerosing cholangitis: Clinical diagnosis and long-term management issues. Liver Transpl 2006; 12: S73-S75. (Pubitemid 44742530)
10. Gautam M, Cheruvattath R, Balan V. Recurrence of autoimmune liver disease after liver transplantation: A systemic review. Liver Transpl 2006; 12: 1813-1824. (Pubitemid 44911808)
11. Demetris AJ. Distinguishing between recurrent primary sclerosing cholangitis and chronic rejection. Liver Transpl 2006; 12: S68-S72. (Pubitemid 44742529)
12. Tamura S, Sugawara Y, Kaneko J et al. Recurrence of primary sclerosing cholangitis after living donor liver transplantation. Liver Int 2007; 27: 86-94. (Pubitemid 46139432)
13. Egawa H, Taira K, Teramukai S et al. Risk factors for recurrence of primary sclerosing cholangitis after living donor liver transplantation: A single center experience. Dig Dis Sci 2009 Jun; 54: 1347-1354.
14. Berquist A, Lindberg G, Saarinen S et al. Increased prevalence of primary sclerosing cholangitis among first-degree relatives. J Hepatol 2005; 42: 252-256. (Pubitemid 40143473)
15. Kim WR, Therneau TM, Wiesner RH, et al. A revised natural history model for primary sclerosing cholangitis. Mayo Clin Proc 2000 Jul; 75: 688-694. (Pubitemid 30441497)
16. Banff Working Group;Demetris AJ, Adeyi O, Bellamy CO et al. Liver biopsy interpretation for causes of late liver allograft dysfunction. Hepatology 2006; 44: 489-501.
17. Graziadei IW, Wiesner RH, Marotta PJ et al. Long-term results of patients undergoing liver transplantation for primary sclerosing cholangitis. Hepatology 1999; 30: 1121-1127. (Pubitemid 29510847)
18. Ljungman P, Griffiths P, Paya C. Definiions of Cytomegalovirus infection and disease in transplant recipients. Immunocomprom Hosts 2002; 34: 1094-1097. (Pubitemid 34289682)
19. Anderson JR, Cain KC, Gelber RD. Analysis of survival by tumor response. J Clin Oncol 1983; 1: 710-719. (Pubitemid 14202071)
20. Egawa H, Uemoto S, Inomata Y et al. Biliary complications in pediatric living related liver transplantation. Surgery 1998; 124: 901-910. (Pubitemid 28520784)
21. Egawa H, Oike F, Buhler L et al. Impact of recipient age on outcome of ABO-incompatible living-donor liver transplantation. Transplantation 2004; 77: 403-411. (Pubitemid 38209740)
22. Kasahara M, Egawa H, Takada Y et al. Biliary reconstruction in right lobe living-donor liver transplantation: Comparison of different techniques in 321 recipients. Ann Surg 2006; 243: 559-566.
23. Weismuller TJ, Wedemeyer J, Kubicka S et al. The challenges in primary sclerosing cholangitis - Aetiopathogenesis, antoimmunity, managemant and malignancy. J Hepatol 2008; 48: 38-57.
24. Hashimoto M, Kinoshita T, Yamasaki M et al. Gene frequencies and haplotypic associations within the HLA region in 916 unrelated Japanese individuals. Tissue Antigens 1994; 44: 166-173. (Pubitemid 24298084)
25. Halme L, Hockerstedt K, Lautenschlager I. Cytomegalovirus infection and development of biliary complications after liver transplantation. Transplantation 2003; 75: 1853-1858. (Pubitemid 36734642)
26. Egawa H, Inomata Y, Uemoto S et al. Biliary anastomotic complications in 400 living related liver transplantations. World J Surg 2001; 25: 1300-1307. (Pubitemid 32952579)
27. Melnick JI, Adam E, DeBakey ME. Possible role of cytomegalovirus infection in atherosclerosis. JAMA 1990; 263: 2204-2207. (Pubitemid 20144500)
28. Bolovan-Fritts CA, Spector SA. Endothelial damage from cytomegalovirus-specific host immune response can be prevented by targeted disruption of fractalkine-CX3CR1 interaction. Blood 2008; 111: 175-182.
29. Streblow DN, Kreklywich C, Yin Q et al. Cytomegalovirus-mediated upregulation of chemokine expression correlates with the acceleration of chronic rejection in rat heart transplants. J Viro 2003; 77: 2182-2194. (Pubitemid 36110031)
30. Miyagawa-Hayashino A, Tsuruyama T, Haga H et al. Arteriopathy in chronic allograft rejection in liver transplantation. Liver Transpl 2004; 10: 513-519. (Pubitemid 38443590)
31. Levitsky J, Singh N, Wagener MM et al. A survey of CMV prevention strategies after liver transplantation. Am J Transplant 2008; 8: 158-161.
32. Goss JA, Shackleton CR, Farmer DG et al. Orthotopic liver transplantation for primary sclerosing cholangitis a 12-year single center experience. Ann Surg 1997; 225: 472-483. (Pubitemid 28079096)